← Azimuth Daily
Capturing data…
Capturing data…
THU, 24 SEPT · 98 ITEMS
"MHRA approves lurbinectedin for extensive-stage small-cell lung cancer" — Dept for Business and Trade · Science & Medicine
This is a regulatory approval announcement: the UK's Medicines and Healthcare products Regulatory Agency () has licensed (Zepzelca) for adults with — the form of small-cell lung cancer that has spread widely. Lurbinectedin is a chemotherapy drug that interferes with gene transcription in cancer cells, and it is generally used after prior . The approval gives UK patients a new treatment option in a disease where post-first-line options are limited.
The claim rests directly on a primary-source announcement from MHRA published on gov.uk, so the core fact — that MHRA granted the approval — is solid and matches independent wire reporting (Reuters). The exact approved patient subgroup is stated in the release but not fully visible in the headline; no conflicting reports appeared in the live search.
Genuinely new: the approval was announced on 23 September 2026, with no recirculation year given.
A week earlier we covered tambotatug pelitecan in the same patient setting — small-cell lung cancer after platinum therapy — so this MHRA approval follows another recent development in that treatment space.